Rationale, design, and baseline characteristics of a randomized trial to assess the effect of cholesterol lowering on the progression of aortic stenosis. The Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) trial

American Heart Journal

Volumn 153, Issue 6, 2007, Pages 925-931

  Chan, Kwan Leung ^a   Teo, Koon ^b   Tam, James ^c   Dumesnil, Jean G ^d  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^b HAMILTON HEALTH SCIENCES   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

^d LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; PLACEBO; ROSUVASTATIN;

ADULT; AORTA STENOSIS; AORTA VALVE REPLACEMENT; ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DEATH; HEART VALVE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AORTIC VALVE; AORTIC VALVE STENOSIS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HEART VALVE PROSTHESIS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PATIENT SELECTION; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SULFONAMIDES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34249740257     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.03.011     Document Type: Article

References (27)

1. Lindroos M., Kupari M., Heillila J., et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 5 (1993) 1220-1225
2. Davies M.J., Treasure T., and Parker D.J. Demographic characteristics of patients undergoing aortic valve replacement for stenosis: relation to valve morphology. Heart 75 (1996) 174-178
3. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol 3 (1997) 630-634
4. Otto C., Kuusisto J., Reichenback D.D., et al. Characterization of the early lesion of "degenerative" valvular aortic stenosis: histological and immunohistochemical studies. Circulation 90 (1994) 844-853
5. O'Brien K.D., Reichenbach D.D., Marcovina S.M., et al. Apolipoproteins B, (a) and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Boil 16 (1996) 523-532
6. Olsson M., Dalsgaard C.-J., Haegerstrand A., et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 23 (1994) 1162-1170
7. Olsson M., Thyberg J., and Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19 (1999) 1218-1222
8. Weiss R.M., Ohashi M., Miller J.D., et al. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 114 (2006) 2065-2069
9. Drolet M.C., Arsenault M., and Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol 41 (2003) 1211-1217
10. Rajamannan N.M., Sangiorgi G., Springett M., et al. Experimental hypercholesterolemia induces apoptosis in the aortic valve. J Heart Valve Dis 10 (2001) 371-374
11. Palta S., Pai A.M., Gill K.S., et al. New insights into the progression of aortic stenosis: implications for secondary prevention. Circulation 101 (2000) 2497-2502
12. Novaro G.M., Tiong I.Y., Pearce G.L., et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 104 (2001) 2005-2009
13. Bellamy M.F., Pellikka P.A., Klarich K., et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 40 (2002) 1723-1730
14. Rosenhek R., Rader F., Loho N., et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation 110 (2004) 1291-1295
15. Fodor J.G., Frohlich J.J., Genest Jr. J.J.G., et al., for the Working Group on Hypercholesterolemia and Other Dyslipidemias. Recommendations for the management and treatment of dyslipidemia: report on the Working Group on Hypercholesterolemia and Other Dyslipidemias. CMAJ 162 (2000) 1441-1447
16. Otto C.M., Burwash I.G., Legget M.E., et al. Prospective study of asymptomatic valvular aortic stenosis: clinical, echocardiographic, and exercise predictors of outcome. Circulation 95 (1997) 2262-2270
17. Lee E., Ryan S., Birmingham B., et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 78 (2005) 330-341
18. Faggiano P., Ghizzoni G., Sorgato A., et al. Rate of progression of valvular aortic stenosis in adults. Am J Cardiol 70 (1992) 229-233
19. Iivanainen A.M., Lindroos M., Tilvis R., et al. Calcific degeneration of the aortic valve in old age: is the development of flow obstruction predictable?. J Int Med 239 (1996) 269-273
20. Freeman R.V., and Otto C.M. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation 111 (2005) 3316-3326
21. Pellikka P.A., Sarano M.E., Nishimura R.A., et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111 (2005) 3290-3295
22. Rajamannan N.M., Subramaniam M., Caira F., et al. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112 suppl I (2005) I-229-I-234
23. Moura L.M., Ramos S.F., Somorano J.L., et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 (2007) 554-561
24. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of extensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 (2005) 2389-2397
25. Roberts W.C., Ko J.M., and Hamilton C. Comparison of valve structure, valve weight, and severity of the valve obstruction in 1849 patients having isolated aortic valve replacement of for aortic valve stenosis (with or without associated aortic regurgitation) studied at 3 different medical centres in 2 different time periods. Circulation 112 (2005) 3919-3929
26. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe, asymptomatic aortic stenosis. N Engl J Med 343 (2000) 611-617
27. Rossebo A., Pederson T., and Skjaerpe T. Design of the Simvastatin and Ezetimide in Aortic Stenosis (SEAS) study. Atherosclerosis 170 (2003) 253